Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Total Non-Current Liabilities (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Total Non-Current Liabilities for 7 consecutive years, with $236.9 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities fell 35.83% to $236.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $236.9 million through Dec 2025, down 35.83% year-over-year, with the annual reading at $236.9 million for FY2025, 35.83% down from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $236.9 million at Beam Therapeutics, down from $338.4 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $635.5 million in Q3 2022, with the low at $234.0 million in Q1 2021.
  • Average Total Non-Current Liabilities over 5 years is $443.6 million, with a median of $425.8 million recorded in 2024.
  • The sharpest move saw Total Non-Current Liabilities surged 346.52% in 2021, then crashed 35.83% in 2025.
  • Over 5 years, Total Non-Current Liabilities stood at $616.3 million in 2021, then fell by 1.54% to $606.9 million in 2022, then fell by 21.22% to $478.1 million in 2023, then decreased by 22.79% to $369.1 million in 2024, then plummeted by 35.83% to $236.9 million in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $236.9 million, $338.4 million, and $344.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.